Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.40 |
| ▸ | TSHR | P16473 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21361246 | 0.87 | CYP3A4 (0.47) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP2D6 | |
| SCHEMBL24120473 | 0.86 | HSD17B10 (0.35) | HSD17B10ALDH1A1HPGDCYP2D6TSHR | |
| SCHEMBL21357467 | 0.86 | SPR (0.37) | HSD17B10ALDH1A1HPGDSMN1; SMN2CYP2D6 | |
| SCHEMBL21361224 | 0.86 | JAK1 (0.39) | — | |
| SCHEMBL21361241 | 0.84 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL21361309 | 0.84 | CYP2D6 (0.35) | ALDH1A1CYP2D6TSHRCYP1A2 | |
| SCHEMBL21361222 | 0.83 | SPR (0.35) | ALDH1A1SMN1; SMN2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL21361242 | 0.83 | SPR (0.35) | SMN1; SMN2CYP2D6CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL21357809 | 0.83 | P2RX7 (0.32) | — | |
| SCHEMBL22954977 | 0.83 | MAPT (0.36) | HSD17B10CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765445-B1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-01-07 | — | — | US | disclosed |
| WO-2019175117-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | CBR3, DDT, CBR1 | HSD17B10 83/4885ALDH1A1 26/4885HPGD 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.